<div><div></div><div>GeoVax Labs completed a private placement structured through a securities purchase agreement, yielding approximately $2.7 million in net proceeds. The transaction issued 2,027,027 pre-funded warrants, exercisable immediately at $0.0001 per share, and Series A and Series B common warrants covering up to 4,054,054 shares at $1.48 per share. Series A warrants expire in five years and Series B in eighteen months. A.G.P./Alliance Global Partners served as exclusive placement agent, earning a 7.0% fee plus expenses and a six-month tail. GeoVax plans to use proceeds for working capital and general corporate purposes.Agreement 1: GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common Warrants<ul><li>Agreement type: Securities purchase agreement for private placement of pre-funded and common warrants</li><li>Counterparty: Purchasers</li><li>Signed / Effective: May 18 2026 / May 19 2026</li><li>Duration / Termination: Series A 5 years; Series B 18 months</li><li>Reason: Raise working capital and general corporate funds</li></ul>Agreement 2: GeoVax Engages A.G.P./Alliance Global Partners as Exclusive Placement Agent for Offering<ul><li>Agreement type: Placement agency agreement for private placement</li><li>Counterparty: A.G.P./Alliance Global Partners</li><li>Signed / Effective: May 18 2026 / May 18 2026</li><li>Duration / Termination: Through closing; 6-month tail</li><li>Reason: Engage agent to place securities in the Offering</li></ul>Original SEC Filing: GeoVax Labs, Inc. [ GOVX ] - 8-K - May. 19, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

GOVXW

GOVX

GeoVax Labs has raised approximately $2.7 million through a private placement of pre-funded and common warrants. The deal includes 2,027,027 pre-funded warrants and Series A and B common warrants for up to 4,054,054 shares. A.G.P./Alliance Global Partners acted as the exclusive placement agent, earning a 7.0% fee. The funds will be used for working capital and general corporate purposes.

TradingView

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

GeoVax Labs

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common Warrants